Alnylam Pharmaceuticals, Inc. Share Price

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 18/06/2024 am IST 5-day change 1st Jan Change
157.3 USD -1.93% Intraday chart for Alnylam Pharmaceuticals, Inc. +2.50% -17.82%
Sales 2024 * 1.87B 157B Sales 2025 * 2.26B 188B Capitalization 20.29B 1,695B
Net income 2024 * -448M -37.42B Net income 2025 * -257M -21.47B EV / Sales 2024 * 10.2 x
Net cash position 2024 * 1.13B 94.14B Net cash position 2025 * 443M 37.01B EV / Sales 2025 * 8.79 x
P/E ratio 2024 *
-45.4 x
P/E ratio 2025 *
-86.1 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.58%
More Fundamentals * Assessed data
Dynamic Chart
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing MT
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating MT
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed MT
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia CI
Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT
Sector Update: Health Care MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower... Our Logo
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension CI
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM
More news
1 day-1.93%
1 week+2.50%
Current month+5.98%
1 month+5.29%
3 months+6.71%
6 months-15.53%
Current year-17.82%
More quotes
1 week
153.24
Extreme 153.24
165.47
1 month
146.79
Extreme 146.79
165.47
Current year
141.98
Extreme 141.975
199.38
1 year
141.98
Extreme 141.975
218.88
3 years
117.58
Extreme 117.58
242.97
5 years
69.11
Extreme 69.11
242.97
10 years
31.38
Extreme 31.38
242.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19/16/19
Director of Finance/CFO 56 13/19/13
Compliance Officer - 21/22/21
Members of the board TitleAgeSince
Director/Board Member 70 18/15/18
Director/Board Member 72 22/22/22
Director/Board Member 68 10/19/10
More insiders
Date Price Change Volume
18/24/18 157.3 -1.93% 777 663
14/24/14 160.4 +0.21% 638,795
13/24/13 160 +0.64% 400,359
12/24/12 159 +1.67% 513,236
11/24/11 156.4 +1.93% 717,051

Delayed Quote Nasdaq, June 18, 2024 at 01:30 am IST

More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
160.4 USD
Average target price
217.9 USD
Spread / Average Target
+35.88%
Consensus